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Adjuvants are used in many vaccines, but their mechanisms of action are not fully under-
stood. Studies from the past decade on adjuvant mechanisms are slowly revealing the
secrets of adjuvant activity. In this review, we have summarized the recent progress in
our understanding of the mechanisms of action of adjuvants. Adjuvants may act by a com-
bination of various mechanisms including formation of depot, induction of cytokines and
chemokines, recruitment of immune cells, enhancement of antigen uptake and presenta-
tion, and promoting antigen transport to draining lymph nodes. It appears that adjuvants
activate innate immune responses to create a local immuno-competent environment at
the injection site. Depending on the type of innate responses activated, adjuvants can alter
the quality and quantity of adaptive immune responses. Understanding the mechanisms
of action of adjuvants will provide critical information on how innate immunity influences
the development of adaptive immunity, help in rational design of vaccines against various
diseases, and can inform on adjuvant safety.
Keywords: adjuvants, mechanisms, innate immunity, cell recruitment and activation, inflammasomes, antigen
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INTRODUCTION
The goal of vaccination is induction of protective immunity and
in some vaccines this can be enhanced by addition of adju-
vants. Adjuvants (Latin word adjuvare, meaning “to help or aid”)
were first described by Ramon as “substances used in combi-
nation with a specific antigen that produced a more robust
immune response than the antigen alone” (Ramon, 1924). Many
diverse classes of compounds have been assessed as adjuvants
including mineral salts, microbials products, emulsions, saponins,
cytokines, polymers, microparticles, and liposomes (Guy, 2007).
Based on their proposed mechanisms of action, vaccine adjuvants
have been broadly divided into delivery systems and immuno-
stimulatory adjuvants (Singh and O’Hagan, 2003). In general,
delivery systems were previously thought to act by providing a
depot while immuno-stimulatory adjuvants activate cells of the
innate immune system (Pashine et al., 2005). However, this classi-
fication is no longer appropriate since now there is evidence that
some delivery systems can activate innate immunity.
Surprisingly, despite the wide use of vaccine adjuvants in bil-
lions of doses of human and animal vaccines, the mechanisms of
action by which they potentiate immune responses are not well
characterized. This is well captured in a famous quote by Janeway
(1989) who observed that adjuvants are “the immunologists’
dirty little secret.” However, recent advances in immunobiological
research have revealed several mechanisms by which adjuvants act.
Available evidence suggests that adjuvants employ one or more of
the following mechanisms to elicit immune responses: (1) sus-
tained release of antigen at the site of injection (depot effect), (2)
up-regulation of cytokines and chemokines, (3) cellular recruit-
ment at the site of injection, (4) increase antigen uptake and
presentation to antigen presenting cells (APC), (5) activation and
maturation of APC [increased major histocompatibility complex
(MHC) class II and co-stimulatory molecules expression] and
migration to the draining lymph nodes, and (6) activation of
inflammasomes (Figure 1) (Cox and Coulter, 1997; Hoebe et al.,
2004; Fraser et al., 2007). In this review, we will address the pro-
posed mechanisms of action of vaccine adjuvants with specific
emphasis on licensed adjuvants (Table 1).
FORMATION OF DEPOT AT THE SITE OF INJECTION
The formation of a depot at the injection site is perhaps the oldest
and most widely recognized mechanism of action of adjuvants.
Antigen trapping and slow release at the site of injection ensures
constant stimulation of the immune system for production of
high antibody titers (Siskind and Benacerraf, 1969). Until recently,
depot effect was considered a classic mechanism of action of many
adjuvants. Glenny et al. (1926) were the first to propose the impor-
tance of depot formation in the adjuvant activity of alum. Antigen
was detected for 2–3 weeks in alumina gel-induced granulomas
(Osebold, 1982). Antigens are simply adsorbed onto the alum but
the binding is proposed to be due to strong electrostatic inter-
action between antigen and alum (Burrell et al., 2000), which
enhanced antigen uptake and presentation by APCs (Mannhal-
ter et al., 1985). Various other adjuvants such as water-in-oil
emulsions [Complete Freunds Adjuvant (CFA)] and biodegrad-
able micro-and nano-particles were shown to act by depot effect
to generate prolonged and sustained high antibody titers (Herbert,
1968; Kreuter, 1988). AS04, an adjuvant combination consist-
ing of monophosphoryl lipid A (MPL) and alum was shown to
induce optimal immune responses only when co-localized with
antigen (Didierlaurent et al., 2009). The presence of alum in
AS04 is important in stabilizing the MPL and antigen within the
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FIGURE 1 | Proposed mechanisms of action of adjuvants. (1) Some
adjuvants presumably form a depot at the site of injection, which is
associated with slow release of antigen. (2) Other adjuvants are associated
with transient secretion of cytokines and chemokines. (3) Secreted cytokines
and chemokines are involved in recruitment of various immune cells to the
injection site. These recruited cells secrete cytokines and chemokines, in turn
attract other immune cells. All these events lead to formation of a local
immuno-competent environment at the injection site. (4) The recruited APCs
express various PRRs both on the surface (TLRs, CLRs) and intracellularly
(NLRs and RLRs), which are recognized and/or are activated by the adjuvants.
(5) This leads to maturation and activation of recruited APCs. Mature APCs
up-regulate the expression of MHC and co-stimulatory molecules. (6) They are
also characterized by increased capacity for antigen processing and
presentation. (7) Mature APCs then migrate to the draining lymph nodes to
interact with antigen-specific B or T cell to (8) activate potent antibody
secreting B cells and/or effector CD8+ T cell responses.
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Table 1 | Mechanisms of action of adjuvants licensed for human use.
Adjuvants Proposed mechanisms of
action
Immune response
activated
Licensed vaccines Reference
Alum No depot effect ↑ Ab responses Many human vaccines (e.g., DTap,
Hib, Hepatitis A, Hepatitis B)
Gavin et al. (2006), Franchi and
Nùñez (2008), Kool et al. (2008a),
McKee et al. (2009), Hutchison
et al. (2012)
NLRP3 activation in vivo?
Independent of TLR signaling
↑ Local cytokines and chemokines ↑Th2 responses
↑ Cell recruitment (eosinophils,
monocytes, macrophages)
Poor Th1 responses
↑ Ag presentation
MF59 No depot effect Balanced Th1 and Th2
responses
Licensed for influenza vaccine
(Fluad®), H5N1 pre-pandemic
vaccine (Aflunov®), H1N1 pandemic
vaccines (Focetria® and Celtura®)
Dupuis et al. (1999), Mosca et al.
(2008), Calabro et al. (2011),
Ellebedy et al. (2011)
NLRP3 independent but
ASC-dependent
Independent of TLR signaling but
MyD88-dependent for Ab responses
↑ Local cytokines and chemokines
↑ Cell recruitment (neutrophils,
macrophages, and monocytes)
↑ Ag uptake
Activate muscle cells
↑ Ag-loaded neutrophils and
monocytes in dLNs
AS04 MPL signals through TLR4 to activate
APCs
↑ Ab responses Licensed for human papilloma virus
(HPV) (Cervarix™), hepatitis B virus
(Fendrix®)
Didierlaurent et al. (2009)
↑ Local cytokines and chemokines
↑ Cell recruitment (DCs and
monocytes)
↑Th1 responses
↑ Ag-loaded DCs and monocytes in
dLNs
AS03 Spatio-temporal co-localization with
Ag
↑ Ab responses Licensed for pandemic flu vaccine
(Pandemrix®)
Morel et al. (2011)
Transient ↑ cytokines locally and in
dLNs
↑ Cell recruitment (granulocytes and
monocytes)
↑ Immune memory
↑ Ag-loaded monocytes in dLNs
Virosomes Ag delivery vehicle ↑ Ab responses Licensed for Inflexal® V and
Invivac® influenza vaccine and
hepatitis A vaccines (Epaxal®)
Glück et al. (1992), Bungener
et al. (2002a,b), Khoshnejad et al.
(2007)
Bind APCs and induce
receptor-mediated endocytosis
↑ CTL responses
Escape endosomal degradation
Ag presentation via MHC class II and
MHC class I to CD4+T cells and
CD8+T cells respectively
Immunopotentiator
Ab, antibody; Ag, antigen; CTL, cytotoxic T lymphocytes; dLNs, draining lymph nodes.
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vaccine, along with providing a depot effect (Didierlaurent et al.,
2009). The cationic adjuvant formulation (CAF) 01, a combina-
tion of dimethyldioctadeclammonium/trehalose-6,6-dibehenate
(DDA/TDB), which is currently in phase I clinical trial, is also
thought to induce long lasting depot effect (Henriksen-Lacey et al.,
2010).
There is no definitive evidence that depot effect significantly
contributes to adjuvant activity (Marrack et al., 2009). In various
studies, it has been shown that surgical removal of the antigen-
alum depot 14 days after immunization had no effect on the
immune responses (Schijns, 2000). Apparently, the adsorption
of antigen to alum was not required for alum adjuvant activ-
ity (Iyer et al., 2003; De Gregorio et al., 2008). It was recently
reported that removal of the injection site 2 h after antigen and
alum administration had no effect on humoral or cell-mediated
immunity (Hutchison et al., 2012). Similarly, MF59 was rapidly
cleared and did not form a depot at the injection site (Ott et al.,
1995). MF59 was distributed and cleared independent of anti-
gen with a half-life of 42 h in the muscle tissue (Dupuis et al.,
1999). Likewise, ISCOMs tend to be rapidly transported to the
draining lymph nodes after administration (Morein and Bengts-
son, 1999). Together, these studies clearly indicate that depot effect
is not required for adjuvant activity of alum, and possibly MF59
or ISCOMs.
UP-REGULATION OF CYTOKINES AND CHEMOKINES
LEADING TO CELLULAR RECRUITMENT AT THE INJECTION
SITE
Recent studies on the mechanisms of adjuvants have focused
on recruitment of innate immune cells at the site of injec-
tion. Particulate adjuvants have been shown to create a local
pro-inflammatory environment to recruit immune cells (Goto
and Akama, 1982). Using genome wide microarray analysis,
Mosca et al. (2008) demonstrated that a cluster of genes encod-
ing cytokines, chemokines, innate immune receptors, interferon-
induced genes, and gene encoding adhesion molecules defined
as “adjuvant core response genes” were commonly modulated
by alum, MF59, and CpG-ODN at the site of injection. Com-
pared with alum and CpG-ODN (TLR9 agonist), MF59 was a
strong modulator of adjuvant core response genes. Chemokines,
which play a critical role in tissue specific migration of immune
cells, were shown to be up-regulated by adjuvants at the injec-
tion site. MF59 significantly up-regulated the expression of CCR2,
a receptor for CCL2, which is involved in monocyte infiltra-
tion. This was in agreement with previous in vitro results show-
ing that MF59 induced release of chemo-attractants like CCL2,
CCL3, CCL3 and CXCL8 (Seubert et al., 2008). Further, studies
in CCR2-deficient mice showed that MF59-induced mononuclear
cell recruitment is CCR2 dependent (Dupuis et al., 2001). Another
oil-in-water emulsion AS03 co-localizes with antigen to trigger
colony-stimulating factor 3 (CSF3) and IL-6, and leukocyte-
recruiting chemokines CCL2, CCL3, and CCL5 at the site of
injection (Morel et al., 2011). Similar cytokine and chemokine
mRNA expression profiles were up-regulated in the draining
lymph nodes (Morel et al., 2011). Likewise, alum-induced infiltra-
tion of immune cells was accompanied by production of chemo-
attractants like CCL2, the neutrophil chemotaxin KC (CXCL1),
and eosinophil chemotaxin eotaxin (CCL11) in the peritoneal
cavity of mice (Kool et al., 2008b). Similarly, a novel adjuvant,
poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP),
induced stronger expression of adjuvant core response genes com-
pared to CpG at the site of injection. Locally, PCEP triggered pro-
duction of pro-inflammatory cytokines and chemokines including
CCL2 (Awate et al., 2012).
Alum promotes Th2-type immune responses and differentia-
tion of B cells resulting in robust antibody production (Grun and
Maurer, 1989). However, the role of Th2 cytokines in the adjuvant
activity of alum is not clearly defined. In vitro studies indicate
that alum-induced activation of macrophages and up-regulation
of co-stimulatory molecules did not depend on IL-4 (Rimaniol
et al., 2004). However, in in vivo studies, alum-induced priming
of B cells through IL-4 producing Gr1+ cells in mouse spleen,
which is required for proliferation of antigen-specific B cells and
for optimal antibody production (Jordan et al., 2004). IL-4 pro-
ducing Gr1+ cells were mainly eosinophils, which appeared within
24 h and induced expansion of B cells and enhanced IgM produc-
tion (Wang and Weller, 2008). Further, studies with eosinophil-
deficient mice showed that the priming of B cells was abolished
after alum injection confirming the central role of eosinophils in
alum-induced Th2-type immune responses (Jordan et al., 2004;
Wang and Weller, 2008). In addition, a study by Serre et al. (2008)
revealed that the Th2-type immune responses generated by alum
may signal through IL-25/IL-17RB and/or IL-6 pathways.
Alum has been shown to activate the complement cascade and
recruit cells from blood to create an inflammatory environment
at the site of injection (Ramanathan et al., 1979; Goto et al.,
1997). Similar to alum, MF59 has been shown to recruit CD11b+
blood mononuclear cells in the mouse muscle (Mosca et al., 2008).
Intra-peritoneal injection of alum-induced rapid cell recruitment
of inflammatory Ly6C+CD11b+ monocytes. The inflammatory
monocytes take up antigen, differentiate into CD11c+ MHC
class II+ DCs in a myeloid differentiation primary response gene
88 (MyD88)-dependent manner and migrate to draining lymph
nodes, where they induced proliferation of antigen-specific T cells
(Kool et al., 2008a). In similar studies by McKee et al. (2009), alum-
induced rapid recruitment of various polymorphonuclear (PMN)
cells including eosinophils, monocytes, neutrophils, DCs, natural
killer (NK), and NKT cells at the site of vaccination. Interestingly,
in cell depletion studies in mice, alum-mediated humoral and cel-
lular responses were independent of mast cells, macrophages, and
of eosinophils (McKee et al., 2009).
MF59-mediated immune cell recruitment to the injection site
has been studied in detail (Calabro et al., 2011). MF59 induced
recruitment of neutrophils, monocytes, eosinophils, macrophages
followed by DCs after i.m. injection in mice. The recruited cells
especially neutrophils, monocytes, and B cells take up both antigen
and adjuvant and traffick to draining lymph nodes. Neutrophils
are the first cells to be recruited at the site of adjuvant injection and
also one of the highest in numbers. However, depletion of neu-
trophils had no impact on the antigen-specific immune responses
induced by MF59 (Calabro et al., 2011). Similar to MF59, admin-
istration of AS03 led to enhanced recruitment of neutrophils,
eosinophils, and monocytes at the site of injection, which take up
antigen and traffick to draining lymph nodes (Morel et al., 2011).
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At the injection site, neutrophils attract other immune cells by
producing increased amounts of chemokines and transport anti-
gen to the draining lymph nodes (Calabro et al., 2011; Morel et al.,
2011). However, the role of neutrophils in adjuvant activity is not
completely clear.
ASO4 induces transient local NFκB activity and cytokine pro-
duction (Didierlaurent et al., 2009). The TLR4 agonist MPL, one
of the components of AS04, stimulated increased numbers of
DCs and monocytes in the draining lymph nodes. Likewise CpG,
a TLR9 agonists, signals through activation of MyD88, IRAK,
and TRAF-6, leading to recruitment of transcriptional factors,
which in turn up-regulates the pro-inflammatory genes and pro-
tein expression (IL-1, IL-6, IL-12, IL-18, and TNF-α) within 3 h
of injection (Klinman et al., 1996; Klaschik et al., 2009). Genes
up-regulated by CpG included cytokines, cell signaling, cell move-
ment, and DNA damage response genes (Klaschik et al., 2010).
One of the roles of cationic liposomes is to recruit immune cells
and increase antigen presentation. Intra-peritoneal injection of
cationic liposome (DDA/MPL) increases influx of neutrophils,
monocytes, macrophages, and activated NK cells in the peritoneal
cavity (Korsholm et al., 2010). Another cationic liposome CAF01
induced recruitment of monocytes to the site of injection and
increased trafficking of liposomes to the draining lymph nodes
(Henriksen-Lacey et al., 2010).
Therefore, adjuvants induce recruitment of various immune
cells to the site of injection, some of which then traffick the
antigen to the draining lymph nodes to induce specific immune
responses. However, the relationship between these recruited cells
and induction of immune responses is not very clear. Depletion
studies suggest that the role of recruited innate immune cells at the
injection site is redundant in the generation of adaptive immune
responses (McKee et al., 2009; Calabro et al., 2011). Interestingly,
these studies were performed by depleting single cell populations.
Identifying the role of a specific cell population in vivo is even
more challenging due to complex environment at the injection
site. Injection of adjuvants often leads to recruitment of a variety
of cell populations and due to high redundancy in the immune sys-
tem, other recruited cells may compensate for the depleted single
cell population. In this regard, mice whose specific cell popula-
tions have been depleted were shown to produce cytokines and
chemokines to recruit innate immune cells and activate T cells
(Seubert et al., 2008; Calabro et al., 2011). Further studies are
required to investigate the detailed relationship between recruited
immune cells and adjuvant activity.
ANTIGEN PRESENTATION
Efficient antigen presentation by MHCs on APCs is important
for the induction of adaptive immune response. It was thought
that many adjuvants including alum, oil-based emulsions, and
microparticles act by “targeting” antigens to APCs resulting in
enhanced antigen presentation by MHC (Guéry et al., 1996; Schi-
jns and Lavelle, 2011). Alum was shown to increase antigen uptake
by DCs and alter the magnitude and duration of antigen presen-
tation (Mannhalter et al., 1985; Morefield et al., 2005). Antigen
adsorption on alum led to an increase in internalization of anti-
gen (Morefield et al., 2005). Recent studies by Flach et al. (2011)
have shown that alum does not enter DCs directly but rather
delivers the antigen via abortive phagocytosis. In this regard, alum
interacts with membrane lipids on DCs leading to lipid sorting,
recruitment of ITAM containing molecules Syk and PI3 activation.
These events eventually lead to uptake of antigen that is adsorbed
on alum, DC activation, and MHC class II expression (Flach et al.,
2011).
The role of adjuvant-induced increased antigen presentation in
development of adaptive immunity has not been clearly evaluated.
Hence, our knowledge is limited regarding the role of this adju-
vant mechanism. Recently, Ghimire et al. (2012) investigated the
impact of antigen presentation on alum adjuvanticity. In addition
to confirming the ability of alum to increase the antigen internal-
ization, the study also showed that alum plays an important role in
reducing the rate of degradation of internalized antigen (Ghimire
et al., 2012). Similarly,MF59 facilitated internalization of gD2 anti-
gen from type 2 herpes simplex virus (HSV) by recruited APCs at
the site of injection and increased phagocytosis in human PBMCs
(Dupuis et al., 1999). Antigen size seems to play an important
role in modulating the antigen presentation efficiency. Large lipid
vesicles end up in early endosome/phagosomes and increases anti-
gen presentation whereas smaller vesicles rapidly localize to late
lysosomes leading to reduced antigen presentation (Brewer et al.,
2004).
ACTIVATION AND MATURATION OF DCs
Activation of DCs is essential for induction of adaptive immune
responses. Increased expression of MHC class II, activation marker
CD86, and maturation marker CD83 leads to enhanced abil-
ity of APCs to induce T lymphocyte activation and differen-
tiation (Coyle and Gutierrez-Ramos, 2001). Freund’s complete
adjuvant, lipopolysaccharide (LPS), liposomes, CpG-ODN, MF59,
AS04, and α-galactosylceramide (α-GAL) have all been shown
to induce DC maturation to enhance adaptive immunity (De
Smedt et al., 1996; De Becker et al., 2000; Copland et al., 2003;
Fujii et al., 2003; Shah et al., 2003). Intra-peritoneal injection
of OVA and alum led to uptake of antigen and maturation of
DCs (Kool et al., 2008a). However, in vitro studies on human
cells have shown that alum and MF59 failed to directly acti-
vate DCs but enhanced the surface expression of MHC class
II and co-stimulatory molecules (CD83 and CD86) on mono-
cytes, macrophages, and granulocytes that resulted in increased
T cell proliferation (Sun et al., 2003; Seubert et al., 2008). Fur-
ther, in vitro activation of DCs by alum has generated conflicting
results. One study suggested that alum failed to induce maturation
and antigen presentation (Sun et al., 2003) where as another study
showed that the activation marker CD86 and antigen presenta-
tion was increased in DCs (Sokolovska et al., 2007). The source
of alum may have been a contributing factor in the conflicting
results.
AS04 has been shown to induce maturation of DCs (via TLR4),
which then trafficks to the draining lymph nodes to activate
antigen-specific T cells (Didierlaurent et al., 2009). Similarly,
CpG induced up-regulation of CD40, CD54, CD80, CD86, and
MHC class II molecules and antigen processing and presenta-
tion in plasmacytoid DCs (pDCs) (Krieg, 2002; Kerkmann et al.,
2003). A novel class of TLR-independent adjuvants, mycobacte-
rial cord factor trehalose-6-6-dimycolate (TDM) and TDB have
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been shown to directly activate DCs through the FcγR-Syk-Card9-
Bcl10-Malt1 pathways, and up-regulates the expression of co-
stimulatory molecules (Werninghaus et al., 2009). Microparticles
such as Poly-lactic-co-glycolic acid (PLGA) did not induce co-
stimulatory molecules expression on bone marrow derived DCs
(BMDCs) but enhanced antigen presentation efficiency (Sun et al.,
2003). DOTAP (1,2-dioleoyl-3-trimethylammonium-propane)-
based cationic liposomes have been shown to induce maturation of
DCs through activation of MAPK (extracellular signal-regulated
kinase and p38), leading to up-regulation of co-stimulatory
molecules (Yan et al., 2007). Likewise, diC14-amidine (3-
tetradecylamino-tert-butyl-N-tetradecylpropion-amidine) based
cationic liposomes up-regulates the expression of CD80 and
CD86 on DCs through specific TLR4/MD2 ligation (Tanaka et al.,
2008). Overall, adjuvants stimulate DC maturation and enhance
the expression of MHC and co-stimulatory molecules, which is
required for efficient T cell activation.
ACTIVATION OF INFLAMMASOMES
Innate immune cells express various pathogen-recognition recep-
tors (PRRs) to recognize infectious agents. In recent years, various
new families of PRRs have been identified including TLRs, C-type
lectin-like receptors (CLRs), nucleotide oligomerization domain
(NOD) like receptors (NLRs), and Retinoic acid-inducible gene-
1 (RIG-1) like receptors (RLRs). Many immunological adjuvants
signal via PRRs or act as ligands for innate immune receptors
(Table 2). In contrast to TLR agonists, particulate adjuvants are
not recognized by specific PRRs but they still induce adaptive
immune responses. The “danger” hypothesis was first advanced by
Matzinger (1994), who proposed that apart from self/non-self dis-
crimination against infection, danger signals from damaged cells
can trigger activation of the immune system. Molecules associ-
ated with tissue damage such as uric acid, nucleotides, adenosine
triphosphate (ATP), reactive oxygen intermediates, and cytokines
are released at the injection site due to tissue damage (Shi et al.,
2003). These non-infectious damage signals have now been named
damage-associated molecular patterns (DAMPs) to distinguish
them from pathogen-associated molecular patterns (PAMPs).
Particulate adjuvants cause local tissue damage and cell death
at the injection site (Kool et al., 2008a). In addition, many adju-
vants induce release of pro-inflammatory cytokines at the site of
injection (Didierlaurent et al., 2009; Calabro et al., 2011; Awate
et al., 2012). These damage signals trigger non-specific activation
of the innate immune system, subsequently stimulating adaptive
immunity. Recently inflammasomes have been one of the most
widely investigated topics due to their potential role in adjuvant
activity. The inflammasome belongs to the NLR family, which
also includes various other receptors, such as the NODs (NOD1-
5), NLRPs (NLRP1-14), NLRP1 (NAIP), NLRC4 (IPAF), and the
major histocompatibility complex II transactivator (CIITA) (Mar-
tinon et al., 2009). Compared to others, NOD-like receptor family,
pyrin-domain-containing 3 (NLRP3) is the most studied inflam-
masome receptor in regards to adjuvant mechanisms. NLRP3, also
known as cryopyrin or NALP3 (NACHT, LRR, and PYD domains-
containing protein 3), is an intra-cytoplasmic multi-protein com-
plex that consists of three components; a NLRP3 receptor, an
apoptosis-associated speck-like protein containing a CARD (ASC)
and a procaspase-1 (Schroder and Tschopp, 2010). Activation of
NLRP3 inflammasome induces caspase-1 activation, which in turn
cleaves proforms of IL-1β, IL-18, and IL-33 to their bioactive
forms (Martinon et al., 2009). The NLRP3 inflammasome can
be activated by various stimuli including DAMPs, environmental
irritants such as asbestos and silica, metabolic stress, and UVB
irradiation (Schroder and Tschopp, 2010). Apart from danger sig-
nals, inflammasomes can be activated by PAMPs such as bacterial
flagellin through NLRC4 activation (Zhao et al., 2011).
Li et al. (2007) reported for the first time that alum-induced
secretion of IL-1β and IL-18 was caspase-1 dependent. Subsequent
in vitro studies by various groups showed that activation of NLRP3
is required for alum-induced IL-1β and IL-18 secretion (Eisen-
barth et al., 2008; Franchi and Nùñez, 2008; Hornung et al., 2008;
Kool et al., 2008a). However, LPS priming to induce pro-IL-1β in
APCs prior to alum stimulation was a pre-requisite for secretion
of IL-1β. Contrary to in vitro studies, the role of inflammasomes
in the adjuvant activity of alum in vivo has yielded conflicting
results. Using NLRP3, ASC and caspase-1 knockout mice, Eisen-
barth et al. (2008) showed that the NLRP3 inflammasome is a
crucial component in the adjuvant activity of alum. NLRP3, ASC,
and caspase-1 knockout mice immunized with OVA adsorbed
on alum, failed to induce antigen-specific antibody responses
(Eisenbarth et al., 2008). Another study by Kool et al. (2008a)
showed that alum-induced lower influx of inflammatory cells in
the peritoneal cavity of NLRP3 deficient mice. They also showed
that alum-mediated activation of adaptive immune responses was
NLRP3-dependent (Kool et al., 2008a). Similar studies done by
Li et al. (2008) showed that NLRP3 deficient mice injected with
alum-adsorbed diphtheria toxoid or OVA vaccine elicited impaired
levels of antigen-specific antibody responses. All these studies indi-
cate that NLRP3 inflammasome is critical in the adjuvant activity
of alum in vivo. In contrast, Franchi and Nùñez (2008) clearly
showed that antigen-specific IgG production was not impaired
in NLRP3 deficient mice following intra-peritoneal injection of
human serum albumin (HSA) in the presence of alum. However,
NLRP3 did affect alum-mediated cellular recruitment suggesting
that inflammasomes might play an important role in activat-
ing innate immunity, but the contribution of inflammasomes in
activation of adaptive immunity remains elusive. The conflicting
results with regard to the role of inflammasomes in adjuvant activ-
ity of alum have been attributed to the differences in the nature of
alum used in different studies, immunization protocols, and the
mouse strains used (De Gregorio et al., 2008; Marrack et al., 2009).
To date, the ligand for NLRP3 has not been identified. Some
theories proposed for alum-mediated activation of NLRP3 include
phagosomal destabilization and release of cathepsin B, low intra-
cellular potassium (K+) concentrations, and generation of reac-
tive oxygen species (ROS) (Petrilli et al., 2007; Hornung et al.,
2008; Kool et al.,2008a). It was proposed that a catabolic product of
nucleotides, uric acid, and ATP released at the site of alum injection
due to cell damage or necrosis act as danger signals for activation of
NLRP3. Saturation of uric acid due to tissue damage forms mono-
sodium ureate crystals (MSU). Phagocytosis of crystalline particles
such as MSU or alum results in phagosomal destabilization and
lysosomal rupture releasing the protease cathepsin B in the cytosol
(Hornung et al., 2008). The released cathepsin B led to activation
Frontiers in Immunology | Immunotherapies and Vaccines May 2013 | Volume 4 | Article 114 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Awate et al. Adjuvant mechanisms
Table 2 | Innate immune receptors activated by vaccine adjuvants.
PRRs Adjuvants Type of immune response
induced
Reference
TLRs TLR1/2 Triacyl lipopeptides Th1, Th2, CTL responses Deres et al. (1989), Schild et al. (1991)
Synthetic Pam3Cys
TLR2/6 Diacyl lipopeptides Th1, Th2, CTL responses Moyle and Toth (2008)
Pam2Cys
TLR2 Pam3Cys Th1, Th2, CTL responses Deres et al. (1989), Schild et al. (1991)
TLR3 Poly I:C Both Th1 and Th2 Tamura and Sasakawa (1983), Choi et al. (2012)
TLR4 LPS, AS04 (MPL) Th1 Sasaki et al. (1997), Casella and Mitchell (2008)
TLR5 Flagellin Th1 and Th2 Didierlaurent et al. (2004), McCarron and Reen (2009)
TLR 7 Imiquimod Th1, CD8+ T cell, CTL responses Wagner et al. (1999), Stanley (2002)
Resiquimod
TLR8 Resiquimod Th1, CD8+ T cell, CTL responses Wagner et al. (1999), Wu et al. (2004)
TLR9 CpG-ODN Th1, CD8+ T cells, CTL responses Kobayashi et al. (1999)
NLRs NOD1/NLRC1 DAP Th1, Th2, Th17 Chamaillard et al. (2003), Girardin et al. (2003a), Fritz
et al. (2007)
NOD2/NLRC2 MDP Th1, Th17 Girardin et al. (2003b), van Beelen et al. (2007), Shaw
et al. (2009)
NLRP1 Toxoids, MDP Th1 Hsu et al. (2008)
NLRP3 Alum, MDP, ATP Th2 Mariathasan et al. (2006), Li et al. (2007), Eisenbarth
et al. (2008)
IPAF/NLRC4 Flagellin Th1 and Th2 Lightfield et al. (2011), Zhao et al. (2011)
NAIP5 Flagellin Th1 and Th2 Kofoed and Vance (2011)
RLRs RIG-1 DNA vectors Th1, CD8+ T cells Luke et al. (2011)
MDA5 Poly I:C Th1, CD8+ T cells Wang et al. (2010)
CLRs Dectin-1 Flagellin, β-glucan/zymosan Th17 LeibundGut-Landmann et al. (2007)
Mincle CAF01 Th1, Th17 CD8+ T cells Gram et al. (2009), Rosenkrands et al. (2011)
Pam3Cys, tri-palmitoyl-S-glyceryl cysteine; LPS, lipopolysaccharide;AS04, adjuvant system04;MPL,monophosphoryl lipidA; CpG-ODN, cytidine-phosphate-guanosine
oligodeoxynucleotides; Poly I:C, polyinosinic-polycytidylic acid; DAP, diaminopimelic acid; MDP, muramyl dipeptide; CAF01, cationic adjuvant formulation-01; TLR, toll-
like receptor; NLR, NOD-like receptors; RLR, RIG-1 like receptors; CLR, C-type lectins; NOD, nucleotide-binding oligomerization domain; NLRP3, NOD-like receptor
family, pyrin-domain-containing 3; IPAF, IL-1β-converting enzyme protease-activating factor; NAIP, neuronal apoptosis inhibitory protein; RIG-1, retinoic acid-inducible
gene-1; MDA5, melanoma differentiation associated gene 5.
of NLRP3 and secretion of pro-inflammatory cytokines IL-1β and
IL-18. Treatment of mice using uricase, a uric acid degrading
enzyme, led to reduced cellular recruitment to draining lymph
nodes in mice injected with alum (Kool et al., 2008a). Similarly,
ATP released by the damaged cells at the injection site has been
shown to indirectly activate NLRP3. Extracellular ATP triggered
stimulation of purinergic P2X7 receptor, resulting in activation of
cation channel for K+ efflux and opening of pannexin-1 pore for
entry of danger signals generated by alum, activate NLRP3 and
subsequently caspase-1 (Solle et al., 2001; Petrilli et al., 2007). Fur-
ther, blocking ROS using chemical scavengers abolished NLRP3
activation in response to MSU suggesting a link between NLRP3
activation and ROS generation (Dostert et al., 2008).
Recently, the role of the inflammasome in adjuvant activity of
MF59 was evaluated (Ellebedy et al., 2011; Seubert et al., 2011).
Two independent studies using NLRP3 deficient mice demon-
strated that NLRP3 is not required for the adjuvant activity of
MF59. However, an adaptor molecule required for the assembly of
inflammasome, ASC was found to be crucial for MF59 adjuvant
activity (Ellebedy et al.,2011). A recent study by Embry et al. (2011)
showed that MPL failed to induce intra-cytoplasmic assembly of
NLRP3 inflammasome leading to failure of caspase-1 activation
and maturation of pro-inflammatory cytokines IL-1β and IL-18.
CONCLUSION
The ultimate goal of vaccination is to generate protection against
disease causing pathogens. Protective immunity against different
pathogens requires different immune responses that can be gener-
ated by using appropriate vaccine adjuvants. Therefore, a detailed
knowledge of the mechanisms of action of adjuvants is very
important in the rational design of vaccines. In recent years, con-
siderable advances have been made in understanding the mecha-
nisms of action of various adjuvants, particularly the activation of
innate immunity via various mechanisms (Table 1). The future of
vaccine adjuvant research is heading toward developing novel
combination adjuvants that consist primarily of PRRs agonists
and particulate adjuvants. While combining different adjuvants
results in potent formulation that can enhance the quality and
quantity of immune response against vaccine antigens, adjuvant
combinations may also have more complex mechanisms of action.
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Safety is a major concern when it comes to adjuvant approval
for human use. Detailed understanding of the mechanisms of
action of adjuvants will provide some insight into their safety.
In addition, since all of the adjuvants approved and currently in
clinical trials are in vaccines administered by injection, there is a
need to identify and develop good mucosal adjuvants. In the com-
ing years, we hope to learn more details of the various mechanisms
of action of adjuvants, which will be valuable in rational vaccine
design and hopefully lead to approval of new adjuvants for use in
vaccines for humans.
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